NCT06772792View on ClinicalTrials.gov

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions

Healthy

Interventions

DRUG

Alendronate

Oral administration

DRUG

Enlicitide Decanoate

Oral administration

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06772792 - A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) | Biotech Hunter | Biotech Hunter